1. Home
  2. KPTI vs WIMI Comparison

KPTI vs WIMI Comparison

Compare KPTI & WIMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • WIMI
  • Stock Information
  • Founded
  • KPTI 2008
  • WIMI 2015
  • Country
  • KPTI United States
  • WIMI China
  • Employees
  • KPTI N/A
  • WIMI N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • WIMI Computer Software: Prepackaged Software
  • Sector
  • KPTI Health Care
  • WIMI Technology
  • Exchange
  • KPTI Nasdaq
  • WIMI Nasdaq
  • Market Cap
  • KPTI 81.1M
  • WIMI 92.2M
  • IPO Year
  • KPTI 2013
  • WIMI 2020
  • Fundamental
  • Price
  • KPTI $0.59
  • WIMI $0.88
  • Analyst Decision
  • KPTI Strong Buy
  • WIMI
  • Analyst Count
  • KPTI 4
  • WIMI 0
  • Target Price
  • KPTI $5.00
  • WIMI N/A
  • AVG Volume (30 Days)
  • KPTI 702.7K
  • WIMI 4.9M
  • Earning Date
  • KPTI 02-27-2025
  • WIMI 01-01-0001
  • Dividend Yield
  • KPTI N/A
  • WIMI N/A
  • EPS Growth
  • KPTI N/A
  • WIMI N/A
  • EPS
  • KPTI N/A
  • WIMI N/A
  • Revenue
  • KPTI $148,442,000.00
  • WIMI $84,137,968.00
  • Revenue This Year
  • KPTI $5.47
  • WIMI N/A
  • Revenue Next Year
  • KPTI $6.33
  • WIMI N/A
  • P/E Ratio
  • KPTI N/A
  • WIMI N/A
  • Revenue Growth
  • KPTI 1.77
  • WIMI 19.25
  • 52 Week Low
  • KPTI $0.58
  • WIMI $0.63
  • 52 Week High
  • KPTI $1.70
  • WIMI $2.92
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 41.95
  • WIMI 41.78
  • Support Level
  • KPTI $0.60
  • WIMI $0.86
  • Resistance Level
  • KPTI $0.69
  • WIMI $0.92
  • Average True Range (ATR)
  • KPTI 0.05
  • WIMI 0.10
  • MACD
  • KPTI -0.00
  • WIMI -0.02
  • Stochastic Oscillator
  • KPTI 18.17
  • WIMI 7.63

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About WIMI WiMi Hologram Cloud Inc.

WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings primarily consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.

Share on Social Networks: